Lemonika31.25 mg/5 ml

Lemonika is used in more than one clinical context depending on the formulation it is dispensed in:

• Demulcent for dry, irritating cough (established local use): As marketed in oral syrup form, Lemonika is indicated for the symptomatic relief of dry cough and throat irritation. It works by coating and soothing the irritated mucous membrane of the throat rather than by any systemic action.
• Urinary alkalinizing / systemic acid-base therapy (combination-product, adjunct use): When formulated together with sodium citrate (and, in some products, potassium citrate) as an oral citrate solution, Lemonika is used to alkalinize the urine in conditions such as uric acid and cystine renal calculi, and as an adjuvant to uricosuric agents in the management of gout. Such citrate combinations are also used to correct chronic metabolic acidosis associated with conditions like chronic renal tubular acidosis and other syndromes of chronic acid retention. These are combination-product indications and are not indications for Lemonika used alone.
• Pharmaceutical excipient/acidulant (general use): Lemonika is widely used as a pH-adjusting, buffering, or flavoring excipient in oral rehydration solutions, effervescent preparations, and other liquid and solid dosage forms, without an intended pharmacologic effect of its own in this role.

The specific indication that applies depends entirely on the actual product/formulation in which Lemonika is dispensed; always follow the labeling of the specific product.

Each unit dose contains Citric Acid Monohydrate as the active/functional ingredient. Depending on the marketed product, Citric Acid Monohydrate may be formulated:

• Alone, as an oral syrup (e.g., approximately 31.25 mg/5 mL or 125 mg/5 mL), for use as a demulcent cough syrup.
• In combination with sodium citrate (and, in some products, potassium citrate) as an oral citrate solution for urinary alkalinization or systemic acidosis correction.
• As an excipient/acidulant/buffering agent within other oral liquid or solid formulations.

Refer to the specific product label for the exact strength and any other active or inactive ingredients present.

Lemonika is the crystalline monohydrate form of citric acid, a naturally occurring tricarboxylic acid found in citrus fruits and produced endogenously in the body as part of the citric acid (Krebs) cycle.

Pharmaceutically, it is used in two broad ways: (1) as a standalone oral syrup ingredient that acts as a demulcent, forming a soothing protective film over irritated pharyngeal mucosa to relieve dry cough, and (2) as a functional component of citrate combination oral solutions (with sodium citrate and/or potassium citrate), where the citrate ion is metabolized to bicarbonate in the liver, producing a systemic alkalinizing effect used to treat metabolic acidosis and to alkalinize the urine. Lemonika is also used generally as a pharmaceutical excipient for pH adjustment, buffering, and flavoring in a wide range of oral formulations.

Lemonika is classified as:

• A demulcent / cough suppressant (local-acting, non-opioid), when used alone in oral syrup form for dry cough.
• A urinary alkalinizer and systemic alkalinizing agent (citrate/bicarbonate precursor), when used as part of a citrate combination oral solution.
• A pharmaceutical excipient (acidulant/buffering/flavoring agent), in other formulations.

Citric Acid Monohydrate has distinct mechanisms of action depending on its use:

As a demulcent (dry cough)

Citric Acid Monohydrate, when taken as an oral syrup, forms a thin protective coating over the irritated mucosa of the pharynx. This soothing film reduces local irritation and the urge to cough, providing symptomatic relief without a centrally-acting antitussive effect.

As a citrate/alkalinizing agent (combination products)

When Citric Acid Monohydrate is combined with sodium citrate (and/or potassium citrate), the citrate ions are absorbed and metabolized via the Krebs cycle to bicarbonate, which is an effective systemic buffer. This raises blood and urinary pH, correcting metabolic acidosis and alkalinizing the urine, which helps dissolve or prevent uric acid and cystine renal stones and reduces the crystallization of uric acid in gout.

As an excipient

In other formulations, Citric Acid Monohydrate functions chemically as a weak acid/buffering agent and flavoring adjunct, without a targeted pharmacologic effect of its own.

Lemonika oral liquid formulations should be measured with an accurate measuring device (oral syringe or measuring cup), not a household spoon. Citrate combination solutions should be diluted in water or juice and taken after meals and at bedtime to reduce gastric irritation. Rinse the mouth with water after each dose to help protect against dental enamel erosion from prolonged acid exposure.

Clinically significant interactions are relevant mainly when Lemonika is used as part of a citrate combination oral solution (with sodium citrate/potassium citrate):

• Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), ACE inhibitors/ARBs, and other potassium-elevating drugs: Concurrent use with potassium-containing citrate combination products increases the risk of hyperkalemia.
• Cardiac glycosides (e.g., digoxin): Alkalinization of urine/blood and shifts in potassium can alter digoxin toxicity risk; use with caution and monitor.
• Aluminum-containing antacids: Citrate can increase gastrointestinal absorption of aluminum; concurrent use with aluminum-containing products should generally be avoided, particularly in patients with renal impairment.
• Other urine-alkalinizing or acidifying drugs: May have additive or opposing effects on urinary pH and should be used together only under medical supervision.

When Lemonika is used alone as a demulcent cough syrup or as a pharmaceutical excipient, no clinically significant drug interactions are established.

When used as directed, Lemonika as a standalone demulcent syrup is generally well tolerated, and clinically significant side effects are not typically documented. With excessive dosing, headache, stomach upset, and diarrhea may occur.

When used as part of a citrate combination oral solution, adverse effects are generally related to the sodium and/or potassium load and include:

• Gastrointestinal upset — nausea, vomiting, diarrhea, abdominal discomfort.
• Symptoms of potassium excess (with potassium-containing products) — listlessness, weakness, mental confusion, tingling of the extremities.
• Symptoms related to sodium/fluid retention (with sodium-containing products) — edema, elevated blood pressure, in susceptible patients.

Prolonged, frequent exposure to acidic Lemonika-containing solutions has also been associated with dental erosion; rinsing the mouth with water after dosing is recommended.

Data on the use of Lemonika during pregnancy are limited. As with any medicine, Lemonika should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Information on excretion of Lemonika into human breast milk is insufficient. Caution is advised, and a physician should be consulted before use of Lemonika while breastfeeding, particularly for citrate combination products intended for systemic effect.

Use Lemonika with caution in the following situations:

• Formulations containing sucrose or other sugars: patients with hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should avoid such Lemonika syrup formulations.
• Citrate combination oral solutions require caution in patients with reduced urinary output, reduced glomerular filtration rate, or any degree of renal impairment; these products should be diluted adequately and taken after meals to minimize gastrointestinal irritation, and periodic monitoring of serum electrolytes is advisable.
• See Contraindications for absolute contraindications (hypersensitivity; and, for citrate combination products, severe renal impairment with oliguria/anuria, untreated Addison's disease, and severe myocardial disease with heart block).
• Dental erosion has been associated with prolonged, frequent exposure to acidic Lemonika-containing solutions; rinse the mouth with water after each oral dose.

As a standalone excipient/demulcent, Lemonika is generally very well tolerated; when it is part of a therapeutic citrate salt combination product, follow that specific product's dosing and monitoring guidance rather than treating Lemonika in isolation.

Overdose of Lemonika as a standalone demulcent syrup may cause headache, stomach upset, and diarrhea. Overdose of citrate combination products containing Lemonika may cause sodium excess (nausea, vomiting, diarrhea, convulsions) or potassium excess/hyperkalemia and metabolic alkalosis (weakness, confusion, tingling of extremities, cardiac arrhythmia), particularly in patients with renal impairment.

If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt specific home treatment; management should be directed by a physician and may require monitoring of serum electrolytes and supportive care.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Lemonika demulcent syrup has established weight/age-based dosing for children from 1 year of age (see Dosage and Administration). For citrate combination oral solutions, pediatric dosing is available, but such products should be used in children only under close medical supervision, with attention to renal function and electrolyte status.

Elderly

No specific dose adjustment is established for Lemonika demulcent syrup in elderly patients. For citrate combination products, elderly patients — who more often have reduced renal function — should be monitored closely for signs of sodium/potassium excess.

Renal impairment

Lemonika demulcent syrup requires no specific adjustment. Citrate combination products are contraindicated in severe renal impairment with oliguria/anuria (see Contraindications) and should be used cautiously with monitoring in lesser degrees of renal impairment.

Hepatic impairment

No specific dose adjustment is established; use with the usual caution applied to any medication in patients with significant hepatic impairment.

For dry cough, Lemonika syrup is typically used for the shortest period needed to relieve symptoms, generally a few days; if cough persists beyond 7 days, worsens, or is accompanied by fever, rash, or persistent headache, medical review is recommended. For citrate combination oral solutions used for chronic metabolic acidosis or urinary alkalinization, treatment duration is usually long-term and guided by periodic monitoring of urinary pH and serum electrolytes, as directed by a physician.

Demulcent (antitussive adjunct); urinary/systemic alkalinizing agent (citrate combination products); pharmaceutical excipient (acidulant/buffering/flavoring agent)

As a demulcent, Citric Acid Monohydrate physically coats and soothes irritated pharyngeal mucosa, reducing the cough reflex triggered by local irritation. As part of a citrate combination product, the citrate component is metabolized to bicarbonate in the liver, which buffers excess hydrogen ions systemically (correcting metabolic acidosis) and alkalinizes the urine (helping prevent/dissolve uric acid and cystine stones and support gout management). As a pharmaceutical excipient, Citric Acid Monohydrate acts chemically as a weak acid to adjust pH, buffer a formulation, or contribute flavor, without an intended pharmacologic effect of its own.

Lemonika demulcent syrup may be used in children from 1 year of age for dry cough, with weight/age-based dosing (see Dosage and Administration). Use in infants below 1 year has not been established and is not recommended without specific medical advice.

For citrate combination oral solutions, pediatric dosing exists for management of metabolic acidosis or urinary alkalinization, but these products should be used in children only under close physician supervision, with monitoring of renal function and serum electrolytes, since safety data in this population are more limited than in adults.